[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.158.98.119. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
March 2001

Cerebrospinal Fluid β-Amyloid and Tau Proteins for the Diagnosis of Alzheimer Disease

Arch Neurol. 2001;58(3):349-350. doi:10.1001/archneur.58.3.349

DEMENTIA DUE TO Alzheimer disease (AD) is a diagnosis based on impaired performance on mental status assessments and evidence of impaired function in daily affairs. Neurologists, geriatricians, and psychiatrists who see many cases of dementia can usually make the diagnosis with confidence. However, among a large group of other physicians, the diagnosis of AD is perceived as uncertain. In order to enhance precision of the diagnosis, biomarkers, such as the combined use of the cerebrospinal fluid (CSF) β-amyloid (Aβ) peptide and tau protein, have recently been the subject of several investigations.13

First Page Preview View Large
First page PDF preview
First page PDF preview
×